Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BALLAD Belgium adjuvant chemotherapy trial for small bowel adenocarcinoma
2024-518349-85-01Phase 3Authorised
- Sponsor
- Belgian Group of Digestive Oncology
- Start
- Nov 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluorouracil, levoleucovorin, oxaliplatin and capecitabine in small bowel adenocarcinoma (SBA) (2 arms), sponsored by Belgian Group of Digestive Oncology. Primary endpoint: Disease-free survival. Planned start Nov 2024; status: authorised.
02
Drugs
fluorouracillevoleucovorinoxaliplatincapecitabine
03
Conditions
small bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on 2024-518349-85-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518349-85-01.